MultiOmyxTM Tumor Infiltrating Lymphocyte Panel*Comprehensive Immunophenotyping from a Single Slide

Immunotherapy is a promising new cancer treatment approach. In order to develop effective precision immunotherapies, it is important to identify immune checkpoint targets and the types and locations of immune cells in the tumor microenvironment; e.g., B cells, T cells, others.

The MultiOmyx Tumor Infiltrating Lymphocyte Panel provides the ideal solution: Quantitative analytical results from every cell on your single FFPE slide.

• Comprehensive immune profiling on a single FFPE slideTissue samples are precious. Unlike IHC assays which must be performed on serial tissue sections, the MultiOmyx Tumor Infiltrating Lymphocyte Panel evaluates 12 key markers on a single slide.

• Unambiguous individual cell phenotypingThe MultiOmyx Tumor Infiltrating Lymphocyte Panel definitively differentiates cell phenotypes and characterizes immune activation and suppression in relation to tumor and stromal regions.

• Advanced bio-image informaticsAnalysis algorithms provide quantitative expression, co-expression, and co-localization of markers.

• Rigorous quality management systemThe MultiOmyx Tumor Infiltrating Lymphocyte Panel is offered by Clarient a NeoGenomics Company, which is CAP accredited and CLIA certified. Quality management overseen by dedicated pathologist and Medical Director.

12 cancer immune markers on a single FFPE slide. Provides quantitative analytical results from every cell.

Figure courtesy of Dr. Luster, Cancer Immunol Res; 2(12); 1125-31. 2014 AACR

CD3 T cell

CD4 TH (helper)

CD8 TC (cytotoxic)

CD20 B cell

CD68 Macrophage

CD56 NK cell

CD45RO Memory T cell

PD-L1 PD1 Ligand

PD1 Inhibit T cell activation

CTLA-4 Inhibit T cell activation

FOXP3 Treg

pan-CK Epithelial Cell

MultiOmyx

Comprehensive immune profilingEvaluate 12 key markers on a single slide. Immune markers shown: CD4 (green), CD8 (red), PD-L1 (magenta), CD68 (cyan), pan-CK (yellow).

IF Color Blends

Unambiguous individual cell phenotypingDifferentiates cell phenotypes and characterizes immune activation and suppression in relation to tumor and stromal regions.

Classification Color Blends

Customer will receive a report summarizing cell counts, percentage, and density for the sample

For additional information and ordering, please contact Rafael Casiano at rafael.casiano@neogenomics.com, 813-330-7555.

In addition, a data package will accompany the report including:• Cell count data in common spreadsheet format → Tab-delimited text files• Registered, normalized AF removed IF images → One per marker per ROI• Image QC mask images → One per marker per ROI• Positive-cell masks → One per marker per ROI• Pre-specified color blends → One per marker per ROI consisting of IF stain (red), cell positive call (green), nuclear mask (blue)• Concatenated multiple sample data

12701 Commonwealth Dr., Suite 9Fort Myers, FL 33913 neogenomics.com | clarient.com

© 2016 NeoGenomics Laboratories, Inc. © 2016 Clarient Diagnostic Services, Inc.All rights reserved.MultiOmyx is a registered trademark of NeoGenomics Laboratories, Inc., which holds a license from GE Healthcare BioSciences Corp.All other trademarks are the property of their respective owners.Rev. 032916

Expression PhenotypeEpithelial / TumorCell Count = 20,501

Non-Epithelial / StromalCell Count = 117,040

Total Cell Count = 137,541

Count % Density Count % Density Count %CD3+ T 10,235 50 2,047 58,580 50 11,716 68,815 50

CD4+ CD4+ 8,247 40 1,649 25,335 22 5,067 33,582 24

CD8+ CD8+ 2,019 10 404 33,125 28 6,625 35,144 26

Remaining 9 single biomarkers

•••

•••

•••

•••

•••

•••

•••

•••

•••

CD3+CD4+ T helper 8,014 39 1,603 23,033 20 4,607 31,047 23

CD3+CD4+FOXP3+ T regulatory 4,176 20 835 3,055 3 611 7,231 5

CD3+CD4+FOXP3+PD-L1+

Immuno-suppression, T regulatory 15 0 3 32 0 6 47 0

CD3+CD4+CD45RO+ Memory T helper 2,294 11 459 17,438 15 3,488 19,732 14

CD3+CD4+PD1+ Anergic T helper 35 0 7 68 0 14 103 0

CD3+CD4+CTLA-4+ Downregulate activated T helper 2,597 13 519 23 0 5 2,620 2

CD3+CD8+ T cytotoxic 1,989 10 398 32,985 28 6,597 34,974 25

CD3+CD8+CD45RO+ Memory T cytotoxic 1,674 8 335 28,556 24 5,711 30,230 22

CD3+CD8+PD1+ Anergic T cytotoxic 744 4 149 2,232 2 446 2,976 2

CD3+CD8+CTLA-4+ Downregulate activated T cytotoxic 1,116 5 223 837 1 167 1,953 1

CD3-CD68+ Macrophage 2,166 11 433 27,116 23 5,423 29,282 21

CD3-CD68+PD-L1+ Immuno-suppression, macrophage 1,463 7 293 6,689 6 1,338 8,152 6

CD3-CD20+ B 233 1 47 5,482 5 1,096 5,715 4

CD3-CD20+PD-L1+ Immuno-suppression, B 52 0 10 63 0 13 115 0

CD3-CD56+ Natural killer 113 1 23 6,271 5 1,254 6,384 5

CD3-CD8+CD56+ Natural killer T 50 0 10 731 1 146 781 1

Pan-CK+PD-L1+ Immuno-suppression, tumor 15,476 75 3,095 15 0 3 15,491 11

•••

* For research use only — Validation pending